出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2012/07/16 16:45:45」(JST)[Wiki en表示]
|Classification and external resources|
|eMedicine||derm/383 emerg/402, emerg/518|
Scarlet fever is a disease caused by erythrogenic toxin (a bacterial exotoxin) released by Streptococcus pyogenes. Once a major cause of death, it is now effectively treated with antibiotics. The term scarlatina may be used interchangeably with scarlet fever, though it is most often used to indicate the less acute form of scarlet fever seen since the beginning of the twentieth century.
Scarlet fever was feared in the pre-antibiotic era, as it was associated with the late post-streptococcal complications of glomerulonephritis and endocarditis leading to heart valve disease, all of which were protracted and often fatal afflictions at the time.
This disease is most common in 4–8 year olds with males and females being equally affected. By the age of 10 years most children have acquired protective antibodies and scarlet fever at this age or older is rare.[dubious – discuss]
It is usually spread by the aerosol route (inhalation) but may also be spread by skin contact or by fomites. Although not normally considered a food borne illness an outbreak due to chicken meat has been reported in China.
Asymptomatic carriage may occur in 15–20% of school-age children.
The incubation period is 1–4 days.
The disease itself is caused by secretion of pyrogenic exotoxins by the infecting Streptococcus. Exotoxin A (speA) is probably the best studied of these toxins. It is carried by the bacteriophage T12 which integrates in to the Streptococcal genome from where the toxin is transcribed. The phage itself integrates into a serine tRNA gene on the chromosome.
The T12 virus itself has not been placed into a taxon by the International Committee on Taxonomy of Viruses. It has a double stranded DNA genome and on morphological grounds appears to be a member of the Siphoviridae.
The speA gene was cloned and sequenced in 1986. It is 753 base pairs in length and encodes a 29.244 kiloDalton (kDa) protein. The protein contains a putative 30 amino acid signal peptide: removal of the signal sequence gives a predicted molecular weight of 25.787 (kDa) for the secreted protein. Both a promoter and a ribosome binding site (Shine Dalgarno sequence) are present upstream of the gene. A transcriptional terminator is located 69 bases downstream from the translational termination codon. The carboxy terminal portion of the protein exhibits extensive homology with the carboxy terminus of Staphylococcus aureus enterotoxins B and C1.
Streptococcal phages other than T12 may also carry the speA gene.
Symptoms and signs
Scarlet fever is characterized by:
- Sore throat
- Bright red tongue with a "strawberry" appearance
- Forchheimer spots (fleeting small, red spots on the soft palate) may occur
- Characteristic rash:
- the rash is fine, red and rough-textured
- blanches upon pressure
- appears 12–72 hours after the fever
- generally starts on the chest, armpits and behind the ears. It may also involve the groin.
- spares the face (although some circumoral pallor is characteristic)
- is worse in the skin folds. These Pastia lines (where the rash runs together in the armpits and groin) appear and can persist after the rash is gone.
- may spread to cover the uvula
- begins to fade three to four days after onset and desquamation (peeling) begins. "This phase begins with flakes peeling from the face. Peeling from the palms and around the fingers occurs about a week later." Peeling also occurs in axilla, groin and tips of the fingers and toes.
Diagnosis of scarlet fever is clinical. The blood test shows marked leukocytosis with neutrophilia and conservated or increased eosinophils, high erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) (both indications of inflammation), and elevation of antistreptolysin O titer. Blood culture is rarely positive but the streptococci can usually be demonstrated in throat culture.
The complications of scarlet fever include septic complications due to spread of streptococcus in blood and immune-mediated complications due to an aberrant immune response. Septic complications—today rare—include ear and sinus infection, streptococcal pneumonia, empyema thoracis, meningitis and full-blown sepsis, upon which the condition may be called malignant scarlet fever.
Immune complications include acute glomerulonephritis, rheumatic fever and erythema nodosum. The secondary scarlatinous disease, or secondary malignant syndrome of scarlet fever, includes renewed fever, renewed angina, septic ear, nose, and throat complications and kidney infection or rheumatic fever and is seen around the eighteenth day of untreated scarlet fever.
An association between scarlet fever and hepatitis has been recognised for several decades. The mechanism of causation is not known.
The rash is the most striking sign of scarlet fever. It usually begins looking like a bad sunburn with tiny bumps and may itch. The rash usually appears first on the neck and face, often leaving a clear unaffected area around the mouth. It then spreads to the chest and back and finally to the rest of the body. In the body creases, especially around the axillae (underarms) and elbows, the rash forms the classic red streaks. On very dark skin, the streaks may appear darker than the rest of the skin. Areas of rash usually turn white (or paler brown, with dark complected skin) when pressed on. By the sixth day of the infection, the rash usually fades, but the affected skin may begin to peel.
Usually there are other symptoms that help to confirm a diagnosis of scarlet fever, including a reddened sore throat, a fever at or above 101 °F (38.3 °C), and swollen glands in the neck. Scarlet fever can also occur with a low fever. The tonsils and back of the throat may be covered with a whitish coating, or appear red, swollen, and dotted with whitish or yellowish specks of pus. Early in the infection, the tongue may have a whitish or yellowish coating. Also, an infected person may have chills, body aches, nausea, vomiting, and loss of appetite.
In rare cases, scarlet fever may develop from a streptococcal skin infection like impetigo. In these cases, the person may not get a sore throat.
When scarlet fever occurs because of a throat infection, the fever typically stops within 3 to 5 days, and the sore throat passes soon afterward. The scarlet fever rash usually fades on the sixth day after sore throat symptoms started, and begins to peel (as above). The infection itself is usually cured with a 10-day course of antibiotics, but it may take a few weeks for tonsils and swollen glands to return to normal.
Other than the occurrence of the diarrhea, the treatment and course of scarlet fever are no different from those of any strep throat. In case of penicillin allergy, clindamycin or erythromycin can be used with success. Patients should no longer be infectious after taking antibiotics for 24 hours. People who have been exposed to scarlet fever should be watched carefully for a full week for symptoms, especially if aged 3 to young adult. It is very important to be tested (throat culture) and if positive, seek treatment.
A drug-resistant strain of scarlet fever, resistant to macrolide antibiotics such as erythromycin, but retaining drug-sensitivity to beta-lactam antibiotics such as penicillin, has emerged in Hong Kong in 2011, accounting for at least two deaths in that city - the first such in over a decade. About 60% of circulating strains of the Group A Streptococcus that cause scarlet fever in Hong Kong are resistant to macrolide antibiotics, says Professor Kwok-yung Yuen, head of Hong Kong University's microbiology department. Previously, observed resistance rates had been 10-30%; the increase is likely the result of overuse of macrolide antibiotics in recent years.
No vaccines are currently available to protect against S. pyogenes infection, although there has been research into the development of one. Difficulties in vaccine development include the considerable strain variety of S. pyogenes present in the environment and the amount of time and number of people needed for appropriate trials for safety and efficacy of any potential vaccine.
The first description of this disease is uncertain. It is possible that Hippocrates described this in a case with a sore throat and skin ulcers but the diagnosis is not entirely clear from the description. The later physicians Avicenna, Rhazes and Ali Abbas described a measles like illness that had more a vivid colour and was more dangerous. Again it is not certain that these descriptions refer to scarlet fever.
The disease appears to have been first described in the medical literature in the book De Tumoribus praeter Naturam by the Sicilian anatomist and physician Giovanni Filippo Ingrassia where he referred to it as rossalia or rosania. It was redescribed by Johann Weyer during an epidemic in lower Germany between 1564 and 1565 who referred to it as scalatina anginosa. The first unequivocal description of scarlet fever was published by Jean Cottyar of Poieters in his book De febre purpura epidemiale et contagiosa libri duo published in 1578 in Paris. Daniel Sennert of Wittenberg described the classical 'scarlatinal desquamation' in 1572 and was also the first to describe the early arthritis, scarlatinal dropsy and ascites associated with the disease.
Bright in 1827 first recognised the involvement of the renal system in scarlet fever.
The association of streptococci and disease was first described in 1874 by Billroth in patients with wound infections. Billroth also coined the genus name Streptococcus. The organism was first cultured in 1883 by the German surgeon Friederich Fehleisen who cultured it from perierysipelas lesions. It received its current name (Streptococcus pyogenes) in 1884 from Rosenbach.
The German physician Friedrich Loeffler was the first in 1884 to show the presence of streptococci in the throats of patients with scarlet fever. Because not all patients with pharyngeal streptococci developed scarlet fever these findings remained controversial for some time. In 1906 the Austrian pediatrician Clemens von Pirquet postulated that disease-causing immune complexes were responsible for the nephritis that followed scarlet fever.
The association between streptocci and scarlet fever was confirmed by Dochez, George, and Dick in the early 1900s.
Bacteriophages were discovered in 1915 by Frederick Twort. His work was overlooked and phages were later rediscovered by Felix d'Herelle in 1917. The specific association of scarlet fever with the Group A streptococcus had to await the development of Lancefield's streptococcal grouping scheme in the 1920s. The Dicks showed that cell-free filtrates could induce the erythematous reaction characteristic of scarlet fever proving that this reaction was due to a toxin. Karelitz and Stempien discovered that extracts from human serum globulin and placental globulin can be used as lightening agents for scarlet fever and this was used later as the basis for the Dick test. The association of scarlet fever and bacteriophages was described in 1926 by Cantucuzene and Boncieu.
The discovery of penicillin and its subsequent widespread use has significantly reduced the mortality of this once feared disease.
The first toxin that causes this disease was cloned and sequenced in 1986 by Weeks and Ferretti.
Dick Test and vaccine
The Dick Test was invented in 1924 and was used to identify those susceptible to scarlet fever. A broth culture filtrate from an erythrogenic toxin producing group A streptococci was injected intracutaneously into susceptible persons. In those susceptible erythematous and oedematous skin reactions developed by 24 hours after injection. A second injection of antitoxin into the site neutralized the reactions. Non-reactors were considered to have sufficient antibodies to the toxin and thus were not susceptible to scarlet fever. The antitoxin was made by injecting horses with the broth filtrates and later collecting the serum from the horse.
Gladys Henry Dick and George Frederick Dick developed a vaccine in 1924 that was later eclipsed by penicillin in the 1940s. Broth filtrates were used as the basis for the patent the Dicks took out on their vaccine in 1924 in the United Kingdom and in 1925 in the United States.
Neither the vaccine nor the Dick Test are in use currently.
Scarlet fever has been used as a plot device or even as a character in a variety of fictional settings
In Act II, Scene V of Rossini's opera, The Barber of Seville, Don Basilio is terrified and sent away to bed at a very crucial point in the plot under the false persuasion that he has contracted the dreaded "febbre scarlattina" (despite the fact that he is told he has turned yellow, rather than red).
Beth, the third sister in Little Women, suffered from the effects of scarlet fever before dying.
Mary Ingalls from the Little House on the Prairie book and TV series lost her sight from the effects of scarlet fever.
In the children's book The Velveteen Rabbit, a toy rabbit's owner contracts scarlet fever and all his toys, including the rabbit, are taken to be burned.
Scarlet fever was a major plot point in American Girl's Kit Kittredge short story Kit Uses Her Head, when Kit, along with her best friends Ruthie Smithens and Stirling Howard, were diagnosed with the disease.
Gene Wilder's character in See No Evil, Hear No Evil went deaf due to scarlet fever.
In Osmosis Jones, the main antagonist, Thrax, is a Scarlet Fever virus intent on getting himself in the medical records by overheating Frank's body in record time.
Persons who suffered from scarlet fever
Myron Florin, the accordionist on The Lawrence Welk Show had scarlet fever as a child. His accordion playing saved his life, as the exertion strengthened his heart back to pre-fever performance.
- List of cutaneous conditions
- Only lysogenized streptococci produce the erythrogenic toxin (pyrogenic exotoxin) which causes the skin rash of scarlet fever
- Scarletina (Scarlet Fever)
- Czarkowski, M. P.; Kondej, B.; Staszewska, E. (2011). "Scarlet fever in Poland in 2009". Przegl Epidemiol 65 (2): 209–212. PMID 21913461.
- Czarkowski, M. P.; Kondej, B. (2010). "Scarlet fever in Poland in 2008". Przegl Epidemiol 64 (2): 185–188. PMID 20731219.
- Yang, S. G.; Dong, H. J.; Li, F. R.; Xie, S. Y.; Cao, H. C.; Xia, S. C.; Yu, Z.; Li, L. J. (2007). "Report and analysis of a scarlet fever outbreak among adults through food-borne transmission in China". J Infect 55 (5): 419–424. DOI:10.1016/j.jinf.2007.07.011.
- Zabriskie, J. B. (1964). "The role of temperate bacteriophage in the production of erythrogenic toxin by Group A Streptococci". J Exp Med 119 (5): 761–780. DOI:10.1084/jem.119.5.761. PMC 2137738. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2137738.
- Krause, R. M. (2002). "A Half-century of Streptococcal Research: Then & Now". Indian J Med Res 115: 215–241. PMID 12440194.
- McShan, W. M.; Ferretti, J. J. (1997). "Genetic diversity in temperate bacteriophages of Streptococcus pyogenes: identification of a second attachment site for phages carrying the erythrogenic toxin A gene". J Bacteriol 179 (20): 6509–6511. PMC 179571. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=179571.
- Weeks, C. R.; Ferretti, J. J. (1986). "Nucleotide sequence of the type A streptococcal exotoxin (erythrogenic toxin) gene from Streptococcus pyogenes bacteriophage T12". Infect Immun 52 (1): 144–150. PMID 262210.
- Yu, C. E.; Ferretti, J. J. (1991). "Molecular characterization of new group A streptococcal bacteriophages containing the gene for streptococcal erythrogenic toxin A (speA)". Mol Gen Genet 231 (1): 161–168. DOI:10.1007/BF00293833. PMID 1753942.
- Dyne P and McCartan K (October 19, 2005). "Pediatrics, Scarlet Fever". eMedicine. emerg/402.
- Balentine J and Kessler D (March 7, 2006). "Scarlet Fever". eMedicine. emerg/518.
- Elishkewitz, K.; Shapiro, R.; Amir, J.; Nussinovitch, M. (2004). "Hepatitis in scarlet fever". Isr Med Assoc J 6 (9): 569–570. PMID 15373323.
- "Second HK child dies of mutated scarlet fever". Associated Press (online). 22 June 2011. http://www.salon.com/wires/health/2011/06/22/D9O0TMJO0_as_hong_kong_scarlet_fever/index.html. Retrieved 23 June 2011.
- "Initiative for Vaccine Research (IVR) - Group A Streptococcus". World Health Organization. http://www.who.int/vaccine_research/diseases/soa_bacterial/en/index3.html. Retrieved 15 June 2012.
- Rolleston, J. D. (1928). "The History of Scarlet Fever". BMJ 2 (3542): 926–929. DOI:10.1136/bmj.2.3542.926.
- Huber, B. (2006). "100 years of allergy: Clemens von Pirquet - his idea of allergy and its immanent concept of disease". Wien. Klin. Wochenschr. 118 (19-20): 573–579. PMID 17136331.
- Cantacuzène, J.; Bonciu, O. (1926). "Modifications subies par des streptocoques d'origine non scarlatineuse au contact de produits scarlatineux filtrès". CR Acad Sci Paris 182: 1185–1187.
- Dick, G. F.; Dick, G. H. (1924). "A skin test for susceptibility to scarlet fever". J Am Med Assoc 82 (4): 265–266. DOI:10.1001/jama.1924.02650300011003.
|Wikimedia Commons has media related to: Scarlet fever|
- Rolleston JD (November 1928). "The history of scarlet fever". British Medical Journal 2 (3542): 926–9. DOI:10.1136/bmj.2.3542.926. PMC 2456687. PMID 20774279. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2456687.
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 連鎖球菌扁桃咽頭炎の合併症 complications of streptococcal tonsillopharyngitis
- 2. 小児におけるA群レンサ球菌（化膿連鎖球菌）性菌血症 group a streptococcal streptococcus pyogenes bacteremia in children
- 3. 免疫能の正常な患者における発熱および発疹 fever and rash in the immunocompetent patient
- 4. 成人におけるA群レンサ球菌（Streptococcus pyogenes）
性菌血症 group a streptococcal streptococcus pyogenes bacteremia in adults
- 5. 小児および思春期における急性感染性咽頭炎の診断へのアプローチ approach to diagnosis of acute infectious pharyngitis in children and adolescents
- Scarlet Fever in an Adult
- Kutsuna Satoshi,Hayakawa Kayoko,Ohmagari Norio
- Internal Medicine 53(2), 167-168, 2014
- NAID 130003392625
- 久田 将之,河北 英明,石崎 哲央,井上 敬一郎,土田 明彦,青木 達哉
- 日本外科系連合学会誌 37(4), 869-875, 2012
- 症例は35歳女性．主訴は発熱および腹痛．整形外科にて手術予定のため入院中，突然に38度以上の発熱認め徐々に下腹部痛と全身状態悪化を認めた．体温38.5℃，血圧82/44mmhg，下腹部に限局する反跳痛伴う強い圧痛を認めた．検査所見では血小板7.7万個/mm3，CRP25.8 mg/dlと著名な炎症反応を認め，骨盤腹膜炎によるDICショックの治療を先行した．治療開始48時間後，ショック状態から回復し …
- NAID 130004838632
- 田中 恒有,入江 嘉仁,今関 隆雄,六角 丘,齊藤 政仁,大喜多 陽平,龍 興一
- 日本心臓血管外科学会雑誌 39(6), 305-308, 2010
- 症例は51歳，男性．近医で心電図異常を指摘され当院に入院した．10歳の時に猩紅熱で入院歴がある．冠動脈CT検査，冠動脈造影検査で，右冠動脈閉塞（RCA），左主幹部（LMT）の冠動脈瘤を含む3枝病変を認め，手術の適応となった．心停止下に動脈グラフトによる冠動脈バイパス術（CABG）および瘤切除を行った．冠動脈造影検査ではグラフトの開存を確認した．病理診断は川崎病による冠動脈瘤であった．川崎病に合併し …
- NAID 130004548274
- Alvro R, Borkan JM, Ferri FF. Scarlet fever. In: Alvero R, Borkan JM, Ferri FF, et al., eds. Ferri's Clinical Advisor. 1st ed. Philadelphia, PA: Elsevier Mosby; 2014. Bisno AL, Stevens DL. Streptococcus pyogenes. In ...
- A streptococcal infection, mainly occurring among children, that is characterized by a red skin rash, sore throat, and fever. ... Thanks to antibiotics many bacterial infections can be effectively treated, including scarlet fever ...
- febrility, febricity, pyrexia, feverishness
- vermilion, orange red